Sign in Create account

Omkar Pharmachem Ltd.

Chemicals · Chemicals & Petrochemicals

BSE: 532167
₹9.73
▼ -0.30 (-2.99%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
40/100
Moderate
Valuation
100/100
Undervalued
Momentum
48/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹10 Cr
PE (TTM)
0.4
Industry median 24.4 (189 companies)
Price to Book
0.3
PEG (TTM)
0.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-57.3
Free Cash Flow
₹0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (238 companies)
EPS Growth (YoY)
-50.00%
as of June 30, 2026
Industry median 39.08% (220 companies)
Net Profit Growth (TTM)
-65.60%
as of June 30, 2026
Industry median 13.45% (212 companies)
Operating Revenue Growth (TTM)
-22.22%
as of June 30, 2026
Industry median 7.93% (209 companies)
Profit Growth (YoY)
-137.04%
as of June 30, 2026
Industry median 23.11% (213 companies)
Revenue Growth (YoY)
-33.33%
as of June 30, 2026
Industry median 17.49% (205 companies)
Current Ratio
5.96
as of March 31, 2026
Industry median 1.87 (237 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.16 (224 companies)
Interest Coverage
57.19
as of June 30, 2026
Industry median 8.97 (221 companies)
Net Margin
-11.11%
as of June 30, 2026
Industry median 7.49% (212 companies)
Operating Margin (EBIT)
-11.11%
as of June 30, 2026
Industry median 11.88% (214 companies)
Operating Margin (TTM)
28.60%
as of June 30, 2026
Industry median 9.75% (219 companies)
Return on Assets
0.34%
as of March 31, 2026
Industry median 4.33% (217 companies)
Return on Capital Employed
0.45%
as of March 31, 2026
Industry median 10.34% (218 companies)
Return on Equity
0.34%
as of March 31, 2026
Industry median 7.52% (219 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (0.3%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.0%
Low 9.7300 · High 10.5300
1W return
11.8%
Low 8.7000 · High 10.5300
1M return
-7.1%
Low 7.0800 · High 10.5300
52W return
-59.5%
Low 7.0800 · High 17.0400
Lifetime High ₹25.0000 (March 15, 2023)
Lifetime Low ₹3.6000 (Jan. 24, 2007)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
9.5
10D
9.2
20D
9.6
50D
12.7
100D
15.2
200D
17.0

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
99.8%
Month avg. delivery
97.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

10.00
Pivot
First resistance10.26
Second resistance10.80
Third resistance11.06
First support9.46
Second support9.20
Third support8.66
Day RSI43.9
Day MFI49.9
Day MACD-1.03
Day MACD signal-1.62

Beta

1M-0.37
3M-0.36
1Y-0.36
3Y0.07

Price change analysis

↓ -7.1%
Over 1 Month
LowHigh
7.0810.53
↓ -59.5%
Over 3 Months
LowHigh
7.0817.04
↓ -59.5%
Over 6 Months
LowHigh
7.0817.04
↓ -59.5%
Over 1 Year
LowHigh
7.0817.04
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 0.4 (own history: 0.9–300.0)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹0 Cr
Net profit (June 30, 2026)
₹-0 Cr
Basic EPS (June 30, 2026)
₹0.0100

Ranks #208 of 221 in Chemicals & Petrochemicals by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter0.03%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 0.03% in Jun 2026 qtr

All shareholding details →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Omkar Pharmachem Ltd - 532167 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Omkar Pharmachem Ltd - 532167 - Shareholder Meeting / Postal Ballot-Outcome of AGM
2 Sep 2026 Corp. Action Omkar Pharmachem Ltd - 532167 - Corporate Action-Fixes Record Date For 31St AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (57.2x)

Weaknesses

  • Low Return on Equity (0.3%)
  • Thin net profit margin (-11.1%)
  • Declining revenue YoY (-33.3%)
  • Declining profit YoY (-137.0%)

Opportunities

  • PEG below 1 (0.00) -- earnings growth outpacing its own valuation
  • PE below 15 (0.4) relative to a typical growth business
  • Trading below book value (PB 0.27)

Threats

  • Down 59.5% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Omkar Pharmachem Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.